000			02807cam a2200325 a 4500
003			EG-GiCUC
008			161204s2016 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.07.M.Sc.2016.Gh.I
100	0		_aGhada Emam Abdelaziz
245	1	0	_aImpact of toll-like receptor 9 gene polymorphism (1237 t / c) on response to therapy in chronic hepatitis C Egyptian patients / _cGhada Emam Abdelaziz ; Supervised Doha Abdelhamid Mokhtar , Rania Ahmed Ahmed Zayed , Dalia Abdelhamid Omran
246	1	5	_aعلى الاستجابه للعلاج في المرضى المصريين المصابين بالالتهاب الكبدي الوبائي سي(T/C 1237) أثر التعدد الشكلى لجين مستقبل شبيه التول 9
260			_aCairo : _bGhada Emam Abdelaziz , _c2016
300			_a122 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
520			_aBackground and aim: Hepatitis C virus (HCV) infection leads to development of liver inflammation, causing morbidity and mortality. Multiple factors influence HCV progression, including genetic factors. Toll-like receptor 9 (TLR9) plays a key role in innate immunity and mutations in the genes encoding this receptor have been associated with progression of liver damage. Our aim is to detect TLR9 1237 T/C (rs5743836) single nucleotide polymorphisms (SNP) in chronic hepatitis C Egyptian patients to determine its association with susceptibility to infection, progression of fibrosis and response to treatment with interferon plus ribavirin. Results: genotype and allelic frequencies of TLR9 1237T/C SNP were not significantly different between studied HCV-positive patients and controls (P=0.373 and 0.405, respectively). TLR9 1237T/C SNP was not associated to treatment response, either ETR or SVR [OR (95% CI) of 0.834 (0.263{u2013}2.643) and 0.698 (0.253{u2013}1.928), respectively) and was not related to advanced stage of fibrosis (P= 0.183). Baseline AFP level was significantly higher in patients with advanced hepatic fibrosis (P= 0.000). Conclusion: TLR9 1237T/C (rs5743836) SNP is not associated to susceptibility to HCV infection, progression of fibrosis or response to combined treatment with Peg-INF plus ribavirin in HCV infected Egyptian patients.
530			_aIssued also as CD
653		4	_aHCV
653		4	_aPolymorphism
653		4	_aTLR9
700	0		_aDalia Abdelhamid Omran , _eSupervisor
700	0		_aDoha Abdelhamid Mokhtar , _eSupervisor
700	0		_aRania Ahmed Ahmed Zayed , _eSupervisor
905			_aNazla _eRevisor
905			_aSoheir _eCataloger
942			_2ddc _cTH
999			_c58884 _d58884